Enovis Corporation ENOV
NYSE · United States · Health Technology
$18.05-0.22 (-1.20%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Rock-bottom prices don’t always mean rock-bottom businesses. The stocks we’re examining today have all touched their 52-week lows, creating a classic investor’s dilemma: bargain opportunity or value trap?
Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Sports Rehabilitation Equipment Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global sports rehabilitation equipment market is experiencing strong growth, driven by the rising incidence of sports injuries, expanding physiotherapy services and increasing awareness of rehabilitation therapies. The market is projected to grow from $4.39 billion in 2025 to $4.79 billion in 2026, representing a compound annual growth ra
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The American Academy of Orthopaedic Surgeons (AAOS) announced that Enovis™ has expanded its support of the AAOS Registry Program, becoming the first industry partner to sponsor multiple AAOS registries. A longtime sponsor of the American Joint Replacement Registry (AJRR), Enovis will now also support the Shoulder & Elbow Registry (SER) through 2027.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.